NEXGEL Projects $35 Million Pro Forma Revenue Following Celularity Acquisition

NEXGEL (NXGL) has officially closed its transaction to acquire the degenerative wound segment from Celularity, a move aimed at expanding its footprint in the specialized medical care market. The announcement was delivered by CEO, President, and Director Adam Levy during the company's Q4 2025 earnings call. This strategic acquisition is designed to integrate Celularity's wound care assets into NEXGEL's existing operational framework. By absorbing this segment, the company seeks to diversify its offerings and scale its commercial reach within the healthcare sector. From a financial perspective, the company provided a specific outlook regarding the impact of the deal. NEXGEL expects that the combined entity will generate pro forma annual revenue of roughly $35 million. While the acquisition represents a significant step in the company's growth strategy, the immediate market impact is expected to be contained. Investors will likely focus on the company's ability to successfully integrate the new segment and realize the projected revenue targets in the coming fiscal periods.